Matrix Metalloproteinases and Glaucoma Risk
Author Information
Author(s): Makedonka Atanasovska Velkovska, Katja Goričar, Tanja Blagus, Vita Dolžan, Barbara Cvenkel
Primary Institution: University Medical Centre Ljubljana
Hypothesis
The study investigates the association of matrix metalloproteinase (MMP) gene polymorphisms with glaucoma risk and treatment response.
Conclusion
Selected MMP SNPs may be associated with the risk of ocular hypertension but not primary open-angle glaucoma, and they do not significantly affect treatment response.
Supporting Evidence
- Carriers of the MMP3 rs3025058 TT genotype had a significantly higher risk of ocular hypertension.
- None of the investigated MMP polymorphisms were associated with response to treatment with latanoprost or SLT.
- The study included a control group of 339 healthy blood donors for comparison.
- Statistical analysis included logistic regression to assess associations between polymorphisms and glaucoma risk.
Takeaway
This study looked at how certain genes might affect the risk of getting glaucoma and how well treatments work, finding some links but not for all cases.
Methodology
The study included a retrospective analysis of 307 patients with primary open-angle glaucoma or ocular hypertension and a prospective analysis of treatment response in 103 patients.
Potential Biases
Potential bias due to the small sample size and limited genetic polymorphisms analyzed.
Limitations
The study had a small sample size and only analyzed a few known polymorphisms.
Participant Demographics
307 patients, including 235 with primary open-angle glaucoma and 72 with ocular hypertension; control group of 339 healthy blood donors.
Statistical Information
P-Value
0.009 for MMP3 rs3025058 association with ocular hypertension risk.
Confidence Interval
95% CI = 1.15–7.62 for MMP3 rs3025058 association.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website